These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 7784310)

  • 21. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
    Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin.
    Morita I; Sato I; Ma L; Murota S
    Endothelium; 1997; 5(2):107-13. PubMed ID: 9237044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors.
    Sirtori CR
    Pharmacol Res; 1990; 22(5):555-63. PubMed ID: 2126139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR; Newton RS
    Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity.
    Burton PM; Swinney DC; Heller R; Dunlap B; Chiou M; Malonzo E; Haller J; Walker KA; Salari A; Murakami S
    Biochem Pharmacol; 1995 Aug; 50(4):529-44. PubMed ID: 7646560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells.
    Yanagita T; Yamamoto K; Ishida S; Sonda K; Morito F; Saku K; Sakai T
    Clin Ther; 1994; 16(2):200-8. PubMed ID: 8062316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
    Jendralla H; Granzer E; von Kerekjarto B; Krause R; Schacht U; Baader E; Bartmann W; Beck G; Bergmann A; Kesseler K
    J Med Chem; 1991 Oct; 34(10):2962-83. PubMed ID: 1656041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in human hepatoma cell line Hep G2. Effects of inhibitors of cholesterol synthesis on enzyme activity.
    Boogaard A; Griffioen M; Cohen LH
    Biochem J; 1987 Jan; 241(2):345-51. PubMed ID: 3036060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
    Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH
    Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
    Feillet C; Farnier M; Monnier LH; Percheron C; Colette C; Descomps B; Crastes De Paulet A
    Atherosclerosis; 1995 Dec; 118(2):251-8. PubMed ID: 8770319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
    Krasovec M; Elsner P; Burg G
    Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
    Slater EE; MacDonald JS
    Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
    Laufs U; La Fata V; Plutzky J; Liao JK
    Circulation; 1998 Mar; 97(12):1129-35. PubMed ID: 9537338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones.
    Ide H; Fujiya S; Aanuma Y; Agishi Y
    Clin Ther; 1990; 12(5):410-20. PubMed ID: 2268863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation.
    Bocan TM; Mazur MJ; Mueller SB; Brown EQ; Sliskovic DR; O'Brien PM; Creswell MW; Lee H; Uhlendorf PD; Roth BD
    Atherosclerosis; 1994 Nov; 111(1):127-42. PubMed ID: 7840808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simvastatin further enhances the hypocholesterolemic effect of soy protein in rabbits.
    Giroux I; Lavigne C; Moorjani S; Jacques H
    J Am Coll Nutr; 1997 Apr; 16(2):166-74. PubMed ID: 9100218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.